Oncology

Showing 15 posts of 324 posts found.

Yourgene wins Australian approval for chemotherapy toxicity screening assay

November 17, 2026
Hospital Management, Oncology, Pharmacy, approvals, chemotherapy, diagnostic testing

Yourgene Health has secured Australian regulatory approval for its Insight DPYD assay, enabling its use in clinical diagnostic testing to …

START and Rome cancer institute partner to expand early-phase trial access in Italy

November 10, 2026
Diagnostics, Oncology, clinical trial collaboration, oncology

The START Center for Cancer Research is partnering with Rome-based Istituti Fisioterapici Ospitalieri (IFO) to establish an early-phase oncology clinical …

AbbVie expands Oxford R&D facility with new £120m UK research commitment

November 9, 2026
Disease, Immunology, Infections and infestations, Neurology, Oncology, R&D, Rare Diseases, facilities, investment

AbbVie has expanded its Oxford research and development (R&D) facility with a new 12,000 sq ft site, strengthening its discovery …

How chronic disease creates opportunity on diagnostic and therapeutic pipelines

November 4, 2026
Asthma & COPD, Cardiology, Corporate, Diabetes, LDTs, Neurology, Oncology, Osteoporosis, Skin, biomarkers, chronic disease, chronic pain, genetic testing, healthcare innovation, investment

As healthcare budgets become increasingly stretched by the demands of coping with long-term illnesses, interest is growing in the manufacturing …

Highlighting the value of lab research for healthcare innovation

November 2, 2026
Cardiology, Devices, Neurology, Oncology, diagnostic tests, healthcare innovation, laboratory science, neurodegenerative disease, oncology

Diagnostic innovation and patient safety have dominated this year’s healthcare-focussed awards to mark European Laboratory Day. Staged by the European …

Medtronic secures CE Mark for new cardiac pacing portfolio

October 30, 2026
Cardiology, Devices, Oncology, cardiology, medical devices

Medtronic has received CE Mark approval for its Vitalis portfolio of five pacemakers, including a device designed for patients who …

Charity commits £800,000 to AI research into late breast cancer recurrence

October 28, 2026
AI, Immunology, Oncology, breast cancer, cytology, oncology, research and development

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate why oestrogen receptor-positive (ER-positive) breast …

Most advanced breast cancer patients treated in community settings, Phesi study finds

October 26, 2026
Oncology, breast cancer, clinical trials, community healthcare, oncology

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings rather than academic centres, potentially …

Amphista doses first patient in AML trial of protein degrader

October 20, 2026
AML, FDA, Oncology, clinical trial, drug development, pharma

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an experimental oral therapy targeting acute …

Sterling doubles ADC manufacturing capacity at Welsh facility

October 16, 2026
ADCs, Corporate, HPLC, Immunology, Infections and infestations, Oncology, manufacturing

Sterling Pharma Solutions has completed a multi-million-pound expansion of its dedicated bioconjugation facility in Deeside, Wales, doubling manufacturing capacity and …

Femtosecond laser cuts lung tumour margin assessment time

October 15, 2026
Devices, Diagnostics, Hospital Management, Oncology, laser imaging, lung disease, tumour

Femtosecond laser imaging has reduced the time needed to assess lung tumour margins from 36 minutes to less than six …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study

October 11, 2026
Chronic Diseases, NHS, Oncology, cardiovascular disease, survey

People in their forties account for almost three-quarters of those who do not attend NHS Health Checks, highlighting the challenge …

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

October 8, 2026
NICE, Oncology, drug recommendation, drug regulation

NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for previously untreated adults with multiple …

From lab breakthrough to NHS treatment: Getting innovative therapies to patients

September 5, 2026
Clinical trials supplies & documentation logistics, Due Diligence, NICE / SMC Submissions, Pharmacovigilance, Regulatory Affairs Oncology

By Chloe Williams and Sarah Ellson Innovative therapies are transforming the treatment landscape for serious diseases, particularly cancer. Advances in …

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026
Oncology

The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the updated prescribing information for Daiichi Sankyo’s Enhertu (trastuzumab), a …

The Gateway to Local Adoption Series

Latest content